Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets

Healthy Clinical Trial

Official title:

A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02266940
• Other study ID #: DS1971-A-E104
• Status: Completed
• Phase: Phase 1
• Start date: November 2014
• Est. completion date: January 2015

Study information

• Verified date: January 2015
• Source: Daiichi Sankyo, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, randomised, 3 treatment, 3 period crossover study. This study is designed to assess the relative bioavailability of DS 1971a from a tablet formulation and a reconstituted oral suspension and the effect of a high fat meal on the relative bioavailability of DS 1971a from the tablet formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female subjects aged 18 to 65 years, inclusive

• Subjects must be in good general health as determined by medical history, physical examination and screening investigations, and be taking no regular medication

• A body mass index (BMI) in the range 18 to 30 kg/m^2, inclusive, and weighing between 50 and 100 kg. BMI is calculated as weight [kg]/(height [m])^2

• Female subjects must be of nonchildbearing potential as follows:

Must be postmenopausal (the last menstrual period was at least 12 months before Screening, and a follicle stimulating hormone [FSH] test at Screening confirms postmenopausal status); or Must be surgically sterile having undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy and/or bilateral tubal ligation

• Willing and able to consume a standard Food and Drug Administration (FDA) high fat meal

• Willing to comply with all study restrictions, including the use of contraception, concomitant medication, and dietary and lifestyle restrictions

• Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study

• Have given written consent to participate after reading the information and consent form, and after having the opportunity to discuss the study with the Investigator or his/her delegate

• Have given written consent to have his/her data entered into The Over-volunteering Prevention System (TOPS)

Exclusion Criteria:

• Clinically relevant abnormal history, physical findings, ECG findings, or laboratory values that could interfere with the objectives of the study or the safety of the subject

• Presence of or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction

• Presence or history of severe adverse reaction to any medicine

• Presence or history of malignant disease

• Acute or chronic infectious disease, including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or C virus (HCV) infection

• Surgery (eg, stomach bypass) or medical condition that might affect absorption of medicines

• Significant illness within 4 weeks before the dose of study medication

• Participation in another clinical study of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical studies during the study and for 3 months after receipt of their final dose of study medication

• Participation in another clinical study with DS-1971a

• Blood pressure (BP) and heart rate in semi supine position at the screening examination outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic; heart rate 40-100 beats/min. Subjects with Stage 1 hypertension (systolic 140 160 mmHg; diastolic 90 100 mmHg) may be enrolled provided they do not have evidence of end organ damage, diabetes or a 10 year cardiovascular risk >20%

• Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73m^2 or an absolute creatinine value above the upper limit of normal (ULN). eGFR will be estimated at Screening using the modification of diet in renal disease (MDRD) equation

• Abnormal ECG waveform morphology at Screening that would preclude accurate measurement of the QT interval duration

• Corrected QT interval (Fridericia's formula) (QTcF) interval duration >430 msec for men or >450 msec for women, obtained as an average from the measurements on duplicate screening ECGs

• Use of any prescription medicine or over-the-counter (OTC) medications, herbal remedies (such as St John's Wort), or food known to be strong inhibitors or strong inducers of cytochrome (CYP) enzymes (also known as CYP450 enzymes) during the 30 days before the dose of study medication; use of any other prescription or OTC medicine, including dietary supplements or herbal remedies, during the 7 days before the first dose of study medication

• Consumption of certain foods or beverages before the dose and throughout the study period

• Loss of more than 400 mL blood during the 3 months before the study, eg, as a blood donor

• Abuse of drugs or alcohol during the 2 years before the first dose of study medication, or intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women)

• Use of tobacco products or nicotine containing products during the 3 months before the dose of trial medication

• Likely possibility that the volunteer will not cooperate with the requirements of the protocol

• Objection by General Practitioner (GP) to volunteer entering the study

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• DS-1971a suspension
DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
• DS-1971a tablet
A 200 mg DS 1971a tablet for oral administration

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research Ltd	London

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics profile of DS-1971a	Plasma concentration time data will be analysed using non compartmental methods. The following PK parameters will be estimated: Cmax, Tmax and AUClast. If data permit, AUC0-inf, CL/F, Vd/F and T½ will be estimated.	3 days from dose administration
Secondary	number and severity of adverse events as a measure of safety and tolerability	number and severity of adverse events as a measure of safety and tolerability	administration of first dose to 10 weeks
Secondary	changes in clinical laboratory profile	haematology, biochemistry, and urinalysis	administration of first dose to 10 weeks
Secondary	changes in physical exam profile	Physical examination profile includes; Height and weight, heart rate, blood pressure (BP), oral temperature and respiration rate, 12 lead electrocardiogram (ECG)	administration of first dose to 10 weeks